Clinical updates from SGO 2023 on PARP inhibitors in ovarian cancer

touchCONGRESS for touchONCOLOGY Listen to renowned experts in gynaecological oncology Dr Domenica Lorusso, Dr Susana Banerjee and Prof. Frederik Marmé review key data presented at SGO 2023 on recent developments in the use of PARP inhibitors in ovarian cancer. Aspects covered include first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. They also discuss how these latest data may impact clinical practice. Clinical themes: Update on first-line PARP inhibitor maintenance in ovarian cancer: Where are we now? (02:31) Selection and sequencing implications for PARP inhibitors in ovarian cancer emerging from the latest data: What should we consider, and when? (19:51) Emerging PARP inhibitor-based neoadjuvant and combination regimens in ovarian cancer: Where are we heading? (40:10) The internationally renowned expert faculty:  Dr Domenica Lorusso, Fondazione Policlinico Universitario A Gemelli, Rome, Italy Dr Susana Banerjee, The Royal Marsden NHS Foundation Trust, London, UK Prof. Frederik Marmé, University Hospital Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs outside of the USA only. This activity is funded by an independent medical education grant from GlaxoSmithKline, and is provided by touchIME. For further information visit our website: https://touchoncology.com/education/congress-sgo-2023-updates-parp-inhibitors-ovarian-cancer/